Flu virus type b
Pro Research Analysisby 
Searched over 200M research papers
Influenza B Virus: Evolution, Immunity, and Vaccine Development
Evolutionary Lineages of Influenza B Virus
Cocirculation of Distinct Lineages
Since 1983, two distinct evolutionary lineages of the influenza B virus have been identified: B/Victoria/2/87-like and B/Yamagata/16/88-like viruses. These lineages were first recognized during the 1988-1989 flu season through hemagglutination-inhibition tests. The B/Victoria lineage was predominant in the United States, while both lineages were found in several Asian countries . Genetic analysis revealed significant differences in the hemagglutinin (HA) genes of these lineages, indicating parallel evolutionary pathways .
Immunity and Antibody Response
Broadly Neutralizing Antibodies
Recent research has identified three human monoclonal antibodies that can protect against both lineages of influenza B virus in mice. Two of these antibodies target distinct regions of the HA molecule, while the third binds to the HA stem, offering cross-protection against both influenza A and B viruses. These findings are promising for the development of a universal flu vaccine .
Age-Dependent Detection Rates
The detection rate of influenza B virus varies with age. Studies have shown that the virus is more commonly detected in children than in non-elderly adults. Among the elderly, the detection rate ranges from 5% to 37%, with significant variability depending on study characteristics such as the number of seasons included and the setting (outpatient vs. inpatient) . This lower detection rate in older adults suggests that public health strategies should consider age-specific factors when addressing influenza B virus .
Vaccine Development and Efficacy
Quadrivalent Vaccines
The inclusion of both influenza B lineages in seasonal flu vaccines has improved protection. Quadrivalent vaccines, which cover both B/Victoria and B/Yamagata lineages, have shown better efficacy compared to trivalent vaccines. However, these quadrivalent vaccines are not yet available worldwide, limiting their global impact .
Reverse Genetics and Vaccine Advances
Advancements in reverse genetics have facilitated the development of new vaccine strategies against influenza B virus. These strategies aim to create broadly protective vaccines that can offer better immunity across different strains and lineages .
Conclusion
Influenza B virus continues to pose a significant health burden, particularly among children and the elderly. The existence of two distinct evolutionary lineages complicates vaccine development and necessitates the inclusion of both lineages in seasonal vaccines. Recent discoveries of broadly neutralizing antibodies and advancements in reverse genetics hold promise for more effective and universal vaccines in the future. Public health strategies must adapt to these evolving insights to better protect vulnerable populations.
Sources and full results
Most relevant research papers on this topic